ESB Financial Corporation (Nasdaq: ESBF), the parent company of ESB
Bank, today announced earnings for the quarter ended September 30, 2014
of $0.26 per diluted share on net income of $4.6 million compared to
earnings of $0.23 per diluted share on net income of $4.0 million for
the quarter ended September 30, 2013, a 13.0% increase in net income per
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical
company focused on developing and commercializing first-in-class, oral
low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies
for the treatment of hypercholesterolemia and other cardiometabolic risk
markers, today announced the closing of its follow-on public offering of
4,887,500 shares of common stock, offered at a price to the public of
$20.00 per share, which includes the exercise in full by the
underwriters of their option to purchase 637,500 additional shares of
BRUSSELS--European Union regulators sought feedback Tuesday on an offer by Air France-KLM Group, Alitalia SpA and Delta Air Lines Inc. that aims to address antitrust concerns over their pact to coordinate trans-Atlantic flights.
By Sara Sjolin, MarketWatch
LONDON (MarketWatch) -- Stock markets climbed across Europe on Tuesday following a report that the European Central Bank is considering buying corporate bonds to further stimulate the eurozone's ailing economy.
European stock markets edged tentatively higher Tuesday, buoyed by forecast-beating gross domestic product and industrial production data out of China, and upbeat earnings from technology heavyweight Apple Inc.
Following a turbulent period last week, which saw many indexes slump to one-year lows on concerns over the health of the global economy and the risk of the eurozone slipping back into recession, the Stoxx Europe 600 was up 0.8% by midmorning Tuesday, reducing its year-to-date loss to 2.4% and decline so far in October to below 7%.
Overnight, figures showed that China's economy grew 7.3% in the third quarter, the slowest rate of growth since the first quarter of 2009 but a touch faster than expected.
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and
joint restoration products for hip, knee, shoulder and spine, announced
today revenue of $57.9 million for the third quarter of 2014, a 4%
increase over $55.7 million in the third quarter of 2013.
Family Dollar Stores, Inc. (“ Family Dollar ”)
(NYSE:FDO), a leading national discount retailer offering name brands
and quality, private brand merchandise, announced today that it has
certified substantial compliance with the Federal Trade Commission’s (“ FTC’s ”)
Request for Additional Information and Documentary Materials (“ Second
Request ”), dated September 8, 2014, regarding the proposed
acquisition (“ Proposed Merger ”) of Family
Dollar by Dollar Tree, Inc. (“ Dollar Tree ”)
(NASDAQ: DLTR). Pursuant to a timing agreement governing the schedule
for the remainder of the FTC staff’s investigation, Family Dollar
understands that Dollar Tree expects to certify substantial compliance
with the FTC by November 7, 2014.
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the
U.S. Food and Drug Administration’s Pulmonary Allergy Drugs Advisory
Committee (PADAC) voted 13-2 to recommend approval of KALYDECO ®
(ivacaftor) in people with cystic fibrosis (CF) ages 6 and older who
have the R117H mutation in the cystic fibrosis transmembrane regulatory ( CFTR )
gene, which is the indication being reviewed by the FDA.
By Wallace Witkowski, MarketWatch
SAN FRANCISCO (MarketWatch) -- A month ago, few people would have thought of investing in companies that specifically made products for fighting the spread of the deadly Ebola virus.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.